18 reports of this reaction
1.7% of all SILVER NITRATE reports
#11 most reported adverse reaction
MOBILITY DECREASED is the #11 most commonly reported adverse reaction for SILVER NITRATE, manufactured by Boiron. There are 18 FDA adverse event reports linking SILVER NITRATE to MOBILITY DECREASED. This represents approximately 1.7% of all 1,031 adverse event reports for this drug.
Patients taking SILVER NITRATE who experience mobility decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MOBILITY DECREASED is a less commonly reported adverse event for SILVER NITRATE, but still significant enough to appear in the safety profile.
In addition to mobility decreased, the following adverse reactions have been reported for SILVER NITRATE:
The following drugs have also been linked to mobility decreased in FDA adverse event reports:
MOBILITY DECREASED has been reported as an adverse event in 18 FDA reports for SILVER NITRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MOBILITY DECREASED accounts for approximately 1.7% of all adverse event reports for SILVER NITRATE, making it a notable side effect.
If you experience mobility decreased while taking SILVER NITRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.